Loading
Life sciences · Review
Frontiers in Microbiology · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Empirical broad-spectrum antibiotics are standard care for febrile neutropenia, but prolonged treatment until neutrophil recovery may increase antimicrobial resistance, toxicity, Clostridioides difficile infection, fungal superinfection, and healthcare burden. Whether antibiotics can be safely discontinued before neutrophil recovery remains uncertain. Methods We systematically reviewed randomized controlled trials comparing early or short-course discontinuation of empirical antibacterial therapy with continuation until neutrophil recovery or an extended fixed course in patients with cancer and febrile neutropenia. MEDLINE, Embase, Cochrane CENTRAL, and ClinicalTrials.gov were searched from inception. Data were pooled using random-effects models. Risk of bias was assessed using the Cochrane RoB 2 tool. Co-primary outcomes were days of antibiotic therapy and all-cause mortality. The review was registered in PROSPERO (CRD420261434782). Results Fifteen trials involving 1,692 participants (1,679 contributing to the mortality analysis) were included. Early discontinuation reduced antibiotic exposure by a mean of 3.43 days (95% CI − 5.59 to −1.27; I 2 = 87.1%), with a larger reduction in children (−5.04 days, 95% CI − 8.55 to −1.54) than adults (−1.52 days, 95% CI − 3.49 to 0.44; subgroup p = 0.0002). All-cause mortality did not differ between groups (Peto odds ratio 1.23, 95% CI 0.64 to 2.36), and the absolute risk difference across all trials was null (0.00, 95% CI − 0.01 to 0.01; I 2 = 0%). No significant differences were observed in new bloodstream infections, treatment failures, or fever recurrences. Conclusion In clinically stable, afebrile patients with cancer-related febrile neutropenia, early antibiotic discontinuation shortened antibiotic exposure, particularly in children, without a detectable increase in mortality or major infectious complications. Larger adult trials are needed to confirm safety. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261434782, CRD420261434782.